These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 8324147

  • 1. Variation in the susceptibility of Bacteroides fragilis group isolates from six Chicago hospitals.
    Hecht DW, Osmolski JR, O'Keefe JP.
    Clin Infect Dis; 1993 Jun; 16 Suppl 4():S357-60. PubMed ID: 8324147
    [Abstract] [Full Text] [Related]

  • 2. Analysis of trends in antimicrobial resistance patterns among clinical isolates of Bacteroides fragilis group species from 1990 to 1994.
    Snydman DR, McDermott L, Cuchural GJ, Hecht DW, Iannini PB, Harrell LJ, Jenkins SG, O'Keefe JP, Pierson CL, Rihs JD, Yu VL, Finegold SM, Gorbach SL.
    Clin Infect Dis; 1996 Dec; 23 Suppl 1():S54-65. PubMed ID: 8953108
    [Abstract] [Full Text] [Related]

  • 3. Susceptibility trends of Bacteroides fragilis group isolates from Buenos Aires, Argentina.
    Fernández Canigia L, Castello L, Di Martino A, Greco G, Legaria MC, Litterio M, Predari SC, Rollet R, Rossetti A, Carloni G, Sarchi MI, Bianchini H.
    Rev Argent Microbiol; 2007 Dec; 39(3):156-60. PubMed ID: 17987852
    [Abstract] [Full Text] [Related]

  • 4. Survey of Bacteroides fragilis group susceptibility patterns in Canada.
    Bourgault AM, Lamothe F, Hoban DJ, Dalton MT, Kibsey PC, Harding G, Smith JA, Low DE, Gilbert H.
    Antimicrob Agents Chemother; 1992 Feb; 36(2):343-7. PubMed ID: 1605600
    [Abstract] [Full Text] [Related]

  • 5. Annual incidence, epidemiology, and comparative in vitro susceptibilities to cefoxitin, cefotetan, cefmetazole, and ceftizoxime of recent community-acquired isolates of the Bacteroides fragilis group.
    Goldstein EJ, Citron DM.
    J Clin Microbiol; 1988 Nov; 26(11):2361-6. PubMed ID: 3235664
    [Abstract] [Full Text] [Related]

  • 6. [Evolution of the sensitivity of Bacteroides group fragilis at the Sevilla University Hospital (1983-1987)].
    Borobio MV, Domínguez MC, Pallares JA, Perea EJ.
    Enferm Infecc Microbiol Clin; 1991 Apr; 9(4):214-8. PubMed ID: 1863620
    [Abstract] [Full Text] [Related]

  • 7. First national survey of antibiotic susceptibility of the Bacteroides fragilis group: emerging resistance to carbapenems in Argentina.
    Fernández-Canigia L, Litterio M, Legaria MC, Castello L, Predari SC, Di Martino A, Rossetti A, Rollet R, Carloni G, Bianchini H, Cejas D, Radice M, Gutkind G, Anaerobe Surveillance Team.
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1309-14. PubMed ID: 22232282
    [Abstract] [Full Text] [Related]

  • 8. In vitro susceptibility of clinical isolates of Bacteroides fragilis and Bacteroides thetaiotaomicron in Japan.
    Watanabe K, Ueno K, Kato N, Muto Y, Bandoh K, Tanaka Y, Jotwani R, Goto M, Shimada K, Shimizu K.
    Eur J Clin Microbiol Infect Dis; 1992 Nov; 11(11):1069-73. PubMed ID: 1295761
    [Abstract] [Full Text] [Related]

  • 9. Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996.
    Snydman DR, Jacobus NV, McDermott LA, Supran S, Cuchural GJ, Finegold S, Harrell L, Hecht DW, Iannini P, Jenkins S, Pierson C, Rihs J, Gorbach SL.
    Antimicrob Agents Chemother; 1999 Oct; 43(10):2417-22. PubMed ID: 10508018
    [Abstract] [Full Text] [Related]

  • 10. Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species.
    Aldridge KE, Ashcraft D, Cambre K, Pierson CL, Jenkins SG, Rosenblatt JE.
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1238-43. PubMed ID: 11257040
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Susceptibility patterns and resistance to imipenem in the Bacteroides fragilis group species in Japan: a 4-year study.
    Bandoh K, Ueno K, Watanabe K, Kato N.
    Clin Infect Dis; 1993 Jun; 16 Suppl 4():S382-6. PubMed ID: 8324152
    [Abstract] [Full Text] [Related]

  • 13. Antimicrobial susceptibility of clinical isolates of Bacteroides fragilis group organisms recovered from 2009 to 2012 in a Korean hospital.
    Yim J, Lee Y, Kim M, Seo YH, Kim WH, Yong D, Jeong SH, Lee K, Chong Y.
    Ann Lab Med; 2015 Jan; 35(1):94-8. PubMed ID: 25553287
    [Abstract] [Full Text] [Related]

  • 14. Prevalence of antimicrobial resistance among clinical isolates of Bacteroides fragilis group in Canada in 2010-2011: CANWARD surveillance study.
    Karlowsky JA, Walkty AJ, Adam HJ, Baxter MR, Hoban DJ, Zhanel GG.
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1247-52. PubMed ID: 22203594
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Antibiotic susceptibility profiles of Bacteroides fragilis and Bacteroides thetaiotaomicron in Japan from 1990 to 1992.
    Tanaka-Bandoh K, Kato N, Watanabe K, Ueno K.
    Clin Infect Dis; 1995 Jun; 20 Suppl 2():S352-5. PubMed ID: 7548596
    [Abstract] [Full Text] [Related]

  • 18. A five-year multicenter study of the susceptibility of the Bacteroides fragilis group isolates to cephalosporins, cephamins, penicillins, clindamycin, and metronidazole in the United States.
    Aldridge KE, Gelfand M, Reller LB, Ayers LW, Pierson CL, Schoenknecht F, Tilton RC, Wilkins J, Henderberg A, Schiro DD.
    Diagn Microbiol Infect Dis; 1994 Apr; 18(4):235-41. PubMed ID: 7924220
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Newer beta-lactam agents and the Bacteroides fragilis group.
    Cuchural GJ.
    Pharmacotherapy; 1991 Apr; 11(2 ( Pt 2)):51S-55S. PubMed ID: 2041832
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.